Enhancement of myoblast microencapsulation for gene therapy.
One method of nonviral-based gene therapy is to implant microencapsulated nonautologous cells genetically engineered to secrete the desired gene products. Encapsulating the cells within a biocompatible permselective hydrogel, such as alginate-poly-L-lysine-alginate (APA), protects the foreign cells from the host immune system while allowing diffusion of nutrients and the therapeutic gene products. An important consideration is which kind of cells is the best candidate for long-term implantation. Our previous work has shown that proliferation and differentiation of encapsulated C2C12 myoblasts in vitro are significantly improved by inclusion of basic fibroblast growth factor (bFGF), insulin growth factor II (IGF-II), and collagen within the microcapsules ("enhanced" capsules). However, the effects of such inclusions on the functional status of the microcapsules in vivo are unknown. Here we found that comparing the standard with the enhanced APA microcapsules; there was no difference in the rates of diffusion of recombinant products of different sizes, that is, human factor IX (FIX, 65 kDa), murine IgG (150 kDa), and a lysosomal enzyme, beta-glucuronidase (300 kDa), thus providing a key requirement of such an immunoprotective device. Furthermore, the creatine phosphokinase activity and myosin heavy chain staining (markers for differentiation of the myoblasts) and the cell number per capsule in the enhanced microcapsules indicated a higher degree of differentiation and proliferation when compared to the standard microcapsules, thus demonstrating an improved microenvironment for the encapsulated cells. Efficacy was tested in a melanoma cancer tumor model by treating tumor induced by B16-F0/neu tumor cells in mice with myoblasts secreting angiostatin from either the standard or enhanced APA microcapsules. Mice treated with enhanced APA-microcapsules had an 80% reduction in tumor volume at day 21 compared to a 70% reduction in those treated with standard APA-microcapsules. In conclusion, enhancement of APA microcapsules with growth factors and collagen did not adversely affect their permeability property and therapeutic efficacy. However, the enhanced differentiation and viability of the encapsulated myoblasts in vivo should be advantageous for long-term delivery with this method of gene therapy.
Li
Anna Aihua
AA
Department of Pediatrics, McMaster University, Health Sciences Centre, Room 3N19, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5.
Shen
Feng
F
Zhang
Tao
T
Cirone
Pasquale
P
Potter
Murray
M
Chang
Patricia L
PL
D000809:Angiotensins / Q000008:administration & dosage / Q000378:metabolism; D000818:Animals; D002214:Capsules; D002454:Cell Differentiation; D049109:Cell Proliferation; D004058:Diffusion; D004339:Drug Compounding; D005164:Factor IX / Q000008:administration & dosage; D015316:Genetic Therapy / Q000379:methods*; D005966:Glucuronidase / Q000008:administration & dosage; D006801:Humans; D020100:Hydrogels / Q000627:therapeutic use*; D007074:Immunoglobulin G / Q000008:administration & dosage; D008546:Melanoma, Experimental / Q000628:therapy; D051379:Mice; D032446:Myoblasts / Q000166:cytology / Q000378:metabolism / Q000637:transplantation*; D047368:Tumor Burden / Q000187:drug effects
D000809:Angiotensins; D002214:Capsules; D020100:Hydrogels; D007074:Immunoglobulin G; D005164:Factor IX; D005966:Glucuronidase